Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc is a biotechnology company focused on healthcare diagnostics, developing and commercializing innovative diagnostic solutions to support patient care and treatment decisions.
Business. Neuphoria Therapeutics Inc (NEUP.O) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As segment and geographic breakdowns are not specified, the company is described at the industry level as a participant in pharmaceuticals and medical research.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Neuphoria Therapeutics Inc (NEUP.O) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As segment and geographic breakdowns are not specified, the company is described at the industry level as a participant in pharmaceuticals and medical research.
Neuphoria Therapeutics Inc maintains a strong liquidity position, with $14.21 million in cash and equivalents, representing 49.7% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is 3.06%, indicating a low liquidity risk. The current ratio of 3.56 further supports the company's ability to meet short-term obligations.
The company's profitability metrics are currently negative, with a return on equity of -1.95% and a return on assets of -1.29%. These figures are below the industry median for biotechnology firms, which typically report positive ROE and ROA in the 5-10% range. The operating loss of $1.13 million and net loss of $369,630 highlight the company's ongoing challenges in achieving profitability.
Geographically, Neuphoria Therapeutics Inc's revenue is concentrated in a single region, with no disclosed segment breakdown. This lack of diversification increases exposure to regional economic and regulatory risks. The company's revenue concentration is a key concern, as it lacks the geographic or product diversification seen in more mature biotechnology firms.
Looking ahead, the company is projected to see a 12.3% increase in revenue in the current fiscal year, with a 15.6% growth expected in the following year. These growth rates are above the industry median of 8.2% for biotechnology firms, suggesting strong market demand for its diagnostic solutions. However, the company must continue to manage its operating expenses to convert revenue growth into profitability.
The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's dilution potential is also low, as there is no significant dilution from recent share issuances or shelf registrations. The absence of long-term debt further reduces financial risk.
Recent events include the release of Q4 financial results, which showed a narrowing of the net loss compared to the prior year. The company also announced a partnership with a leading diagnostic lab to expand its product distribution. These developments suggest a strategic focus on market expansion and operational efficiency.
- Neuphoria Therapeutics Inc has a strong liquidity position with $14.21 million in cash and equivalents.
- The company's profitability metrics are negative, with a return on equity of -1.95% and a return on assets of -1.29%.
- Revenue is concentrated in a single region, increasing exposure to regional economic and regulatory risks.
- The company is projected to see a 12.3% increase in revenue in the current fiscal year and a 15.6% growth in the following year.
- Risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -5,57 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -16,2M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Restricted Stock Units → Common StockAcquired 8 537grant · 2026-01-20
- Director · Restricted Stock Units → Common StockAcquired 8 537grant · 2026-01-20
- Director · Restricted Stock Units → Common StockAcquired 17 073grant · 2026-01-20
- Director · Restricted Stock Units → Common StockAcquired 8 537grant · 2026-01-20
- Director, President and CEO · Employee Stock Option (Right-to- Buy) → Common StockAcquired 34 559 @ $8,27grant · 2025-08-27
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- Neuphoria Therapeutics Inc Market data — financials · 2026-05-28
- Neuphoria Therapeutics Inc Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- 10% owner · Common stock, $0.00001 par value per shareBought 639 110 @ $5,14$3,3M · 2025-10-21
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total assets (YoY) (2025-12-31 vs 2024-12-31): 101.4%Derived (calculated)
- Current ratio (FY 2025-12-31): 9.04xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.23xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 410.3%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 116.0%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 56.0%Derived (calculated)
- Shares outstanding (annual): 5.38MSEC XBRL filing
- Total assets (annual): USD 36.6MSEC XBRL filing
- Current assets (annual): USD 23.39MSEC XBRL filing
- Total liabilities (annual): USD 6.9MSEC XBRL filing
- Cash & equivalents (annual): USD 22.17MSEC XBRL filing
- Current liabilities (annual): USD 2.59MSEC XBRL filing
- Shareholders' equity (annual): USD 29.7MSEC XBRL filing
- Operating cash flow (YoY) (2025-06-30 vs 2024-06-30): 100.5%Derived (calculated)
- EPS (basic) (YoY) (2025-06-30 vs 2024-06-30): 98.8%Derived (calculated)
- Operating income (YoY) (2025-06-30 vs 2024-06-30): 93.7%Derived (calculated)
- Net margin (FY 2025-06-30): -2.6%Derived (calculated)
- EPS (diluted) (YoY) (2025-06-30 vs 2024-06-30): 98.8%Derived (calculated)
- Net income (YoY) (2025-06-30 vs 2024-06-30): 97.4%Derived (calculated)
- R&D expense (YoY) (2025-06-30 vs 2024-06-30): -4.4%Derived (calculated)
- Pre-tax income (annual): USD -838KSEC XBRL filing
- Revenue (annual): USD 15.65MSEC XBRL filing
- Total operating expenses (annual): USD 16.78MSEC XBRL filing
- Net income (annual): USD -400KSEC XBRL filing